Heart rhythm device under the microscope: new study tracks Long-Term safety
NCT ID NCT05839873
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 62 people with non-ischemic structural heart disease who have recurrent, drug-resistant ventricular tachycardia. They are treated with the FlexAbility SE ablation catheter, which uses heat to destroy small areas of heart tissue causing the abnormal rhythm. Researchers will track serious complications and whether patients remain free of VT, death, or need a heart transplant for one year after the procedure.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
FlexAbility SE Ablation Catheter (device used to destroy heart tissue causing abnormal rhythms)
What this could lead to
If successful, this could confirm that the FlexAbility SE catheter is a safe and effective option for controlling ventricular tachycardia in patients with non-ischemic structural heart disease.
What could go wrong
This is an observational post-approval study with only 62 participants and no comparison group, so results may not apply to all patients. Risks include procedure-related serious adverse events and VT recurrence.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VENTRICULAR TACHYCARDIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Baylor Scott & White Heart & Vascular Hospital
Dallas, Texas, 75226, United States
-
Carolinas Medical Center
Charlotte, North Carolina, 28203, United States
-
Integris Baptist Medical Center
Oklahoma City, Oklahoma, 73112, United States
-
Kansas City Cardiac Arrhythmia Research Foundation
Overland Park, Kansas, 66211, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Medical University of South Carolina
Charleston, South Carolina, 29425, United States
-
NCH Healthcare System
Naples, Florida, 34102, United States
-
St. Vincent Hospital
Indianapolis, Indiana, 46240-0970, United States
-
University of Utah Hospital
Salt Lake City, Utah, 84132, United States
-
VA Medical Center Minneapolis
Minneapolis, Minnesota, 55417, United States
-
Vanderbilt Heart & Vascular Institute
Nashville, Tennessee, 37232, United States